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Several previous linkage scans in type 2 diabetes (T2D) families indicated a putative susceptibility locus on chromosome 12q15–q22, while
the underlying gene for T2D has not yet been identified. We performed a region-wide association analysis on 12q15–q22, using a dense set of
>500 single-nucleotide polymorphisms (SNPs), in 1492 unrelated Japanese individuals enrolled in this study. We identified an association between
T2D and a haplotype block spanning 13.6 kb of genomic DNA that includes the entire SOCS2 gene. Evolutionary-based haplotype analysis of
haplotype-tagging SNPs followed by a ‘‘sliding window’’ haplotypic analysis indicated SNPs that mapped to the 5V region of the SOCS2gene to be
associated with T2D with high statistical significance. The SOCS2 gene was expressed ubiquitously in human and murine tissues, including
pancreatic h-cell lines. Adenovirus-mediated expression of the SOCS2 gene in MIN6 cells or isolated rat islets significantly suppressed glucose-
stimulated insulin secretion. Our data indicate that SOCS2 may play a role in susceptibility to T2D in the Japanese.
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0028, Japan.Type 2 diabetes (T2D) is a complex group of disorders
characterized by two distinct pathophysiological defects—
impaired insulin secretion from pancreatic h cells and insulin
resistance in muscle, fat, and the liver [1]. While genetic factors
are known to affect both of these components [2], the search for
the susceptibility gene(s) has proven to be a challenge. Studies of
selected candidate genes for T2D have succeeded in identifying6) 446 – 458
www.el
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substantial proportion of common T2D: the Pro12Ala variant
of the peroxisome proliferative activated receptor, gamma
(PPARG) and the Glu23Lys variant of the potassium inwardly-
rectifying channel, subfamily J, member 11 (KCNJ11) (for a
review, see [3]). These variants may contribute significantly to
the risk of T2D, conferring insulin resistance on hepatic, muscle,
and fat tissues (PPARG, Pro12Ala) and a relative insulin
secretory deficiency (KCNJ11, Glu23Lys). Associations be-
tween each variant and T2D were tested in different racial and
ethnic groups and widely reproduced with modest estimated
odds ratios (ORs) of 1.2–1.5. Such studies of candidate genes
are, however, largely limited to genes coding for proteins
involved in known glucose homeostasis. In contrast, genome-
wide linkage scans for T2D should not presume any prior
knowledge of the mechanisms underlying glucose/insulin
regulation. To date, multiple studies in different racial groups
have been performed and a number of possible susceptibility loci
for both T2D and T2D-related traits were identified throughout
the genome. However, only the NIDDM1 locus on chromosome
2q has been mapped to a single gene, calpain 10 [4]. As in many
other cases of common multifactorial diseases, phenotypic
variability and polygenic inheritance in T2D seem to be adverse
factors that complicate and reduce the power of linkage analysis.
The case of the hepatocyte nuclear factor 4, alpha (HNF4A)
gene is complicated but raises many interesting possibilities.
The HNF4A is a transcription factor important for the
development, differentiation, and function of pancreatic h cells
(for a review, see [5]). Initially, mutations in the HNF4A gene
were identified as a cause of MODY1 (maturity-onset diabetes
of the young, type 1), an early onset monogenic subtype of
diabetes [6]. A number of T2D linkage studies, on the other
hand, found evidence of linkage to 20q12–q13.1 [7], where the
HNF4A gene is located. Taken together, these observations
make HNF4A an excellent functional and positional candidate
for T2D. Recent studies have found an association between T2D
and four common single-nucleotide polymorphisms (SNPs) in
the P2 promoter region, which lies 45 kb upstream of the liver-
specific promoter and is the primary transcription start site in the
h cell [8,9]. Of these, SNP rs2144908 demonstrated the
strongest, though marginal, association with T2D, with ORs
of 1.33 (95% CI 1.06–1.65) in a Finnish population and 1.46
(1.12–1.91) in an Ashkenazi Jewish population. Of note, in both
studies, the risk haplotype was thought to explain a large
proportion of the evidence of linkage to 20q12–q13.1.
Genome-wide SNP association studies using genotypes of
numerous samples with hundreds of thousands of SNPs and the
use of linkage disequilibrium (LD) and haplotype-association
mapping have been proposed as a powerful and promising
approach to the identification of genes with small effects, often
seen in complex traits. In fact, such strategies are beginning to
reveal novel and complex disease-related genes, e.g., for
myocardial infarction and rheumatoid arthritis [10–12]. How-
ever, further development of cost-efficient SNP genotyping and
characterization of the haplotype structure of the human
genome are also needed. For some time, fine-scale LD and
association mapping of susceptibility candidate loci identifiedby linkage studies could be an effective intermediate technique
for identifying T2D genes. Such candidate loci, showing strong
evidence of being replicated linkage signals for T2D, include
chromosomes 12q [13], 1q [14–16], 8p [17], and 3q [18]. In
this study, we performed a region-wide analysis of an
association study for T2D with a dense set of >500 SNPs on
a 27-Mb region of chromosome 12, using 1492 unrelated
Japanese individuals. Our approach, which included identifi-
cation of the susceptibility LD block followed by evolutionary-
based haplotype analysis of haplotype-tagging SNPs (htSNPs),
was useful in demonstrating an association between T2D and
the suppressor of cytokine signaling 2 (SOCS2) gene.
Results
Selection of SNPs
To identify the T2D susceptibility gene on human chromo-
some 12q, we first examined the results of published linkage
studies [16,19–22] and found that linkage peaks on chromo-
some 12q were quite broad and relatively confusing. At least
two separate 12q regions have been identified with supportive
evidence, one near the NIDDM2/MODY3 locus (in 12qter) and
the other more centromeric (12q15–q22). In this study, we
decided to target the 12q15–q22 region. Our target region
corresponded to a 27-Mb interval between two STS markers,
D12S375 and D12S362, which encompasses the 1-LOD-drop
support interval of linkage signals, extending from 80 to 100
cM on chromosome 12 when adjusted for the positions of
genetic markers using the Marshfield Genetic Map as a
reference. The region thus included neither the linkage signals
identified as the NIDDM2locus by Mahtani et al. [23] nor
signals identified by Shaw et al. [24] in their Australian
pedigree. Our target region included a total of 125 genes based
on the National Center for Biotechnology Information (NCBI)
Build 34 human genome assembly. We subsequently searched
for SNP markers within the region with the following criteria:
(1) suitability for designing optimal TaqMan high-throughput
genotyping [25]; (2) mapping to the gene-centric region, which
we assigned to an interval between 10 kb upstream of the
transcription start site and 10 kb downstream of the final exon;
(3) an average distance of 10 kb between adjacent SNPs
whenever possible; and (4) common SNPs with a minor allele
frequency (MAF) >0.15 based on the genotype data of 46
Japanese control individuals supplied by Applied Biosystems
(unpublished data).
We initially obtained a total of 652 TaqMan genotyping
probes from Applied Biosystems and genotyped an additional
111 Japanese control individuals to assess the genotyping quality
(a total of 157 ‘‘genotyping and quality’’ controls, combining 46
and 111 individuals). After excluding SNPs with ambiguous
genotyping qualities, those with significant deviations from the
Hardy–Weinberg equilibrium ( p value <0.05, m2 test) or with
MAF <0.10, a total of 585 SNPs were selected as the Gene-
Centric, Evenly Spaced Common SNPs and used for further
association testing (a complete list of SNPs is available in
Appendix A1 and a statistical summary is shown in Appendix
H. Kato et al. / Genomics 87 (2006) 446–458448A2; appendices are in the supplementary material). Of these, 536
SNPs (91.6%) were mapped within 91 genes (72.8% of the total
target genes), with an average distance of 12.5 kb, and 49 were
in intergenic regions. The average MAF of the 585 SNPs was
0.34 T 0.11 (SD). There were a significant number of allelic
associations among the SNPs, mostly between two or three
adjacent SNPs (data not shown). When SNP haplotype blocks
were generated by the LD-based algorithm of Gabriel et al. [26],
we identified 129 independent SNP haplotype blocks.
Association study
To reduce the time and cost of genotyping, we designed a
large, modified two-stage case–control association analysis in
the 1492 unrelated Japanese individuals with the 585 Gene-
Centric, Evenly Spaced Common SNPs on chromosome 12q
(Appendix B provides an overview of the study design).
In Stage 1 (Discovery panel), we genotyped 147 Japanese
individuals with T2D at all 585 SNP loci and compared allelic
frequencies with those of 157 genotyping and quality controls
(see above), using a standardm2 test. In Stage 1, we selected SNP
markers with a relatively high significance level of a < 0.10 to
increase statistical power for detecting associations. This also
meant most of the SNPs selected at this stage were likely to be
false positives. Thirty-seven SNPs were selected in Stage 1
(Appendix A1). We noticed that the number of SNPs selected
was fewer than expected (see below), and this was probably due
to the presence of marker–marker associations among SNPs.
For the 37 SNPs selected in Stage 1, we genotyped an additional
259 control and 188 T2D individuals, pooled genotypic data,
and regarded this expanded panel as Stage 1E (Expanded panel;
a total of 416 control and 335 T2D individuals). We chose a
significance level of a < 0.05 in this pooled Stage 1E and
selected 9 of 37 SNPs (SNP017, SNP152, SNP260, SNP262,
SNP378, SNP380, SNP488, SNP489, and SNP514).
Next, we tested the nine SNPs selected in Stage 2, an
independent replicative panel consisting of 376 T2D subjects
and 365 control subjects, with an increased significance levelTable 1
Results of association tests for nine SNPs in Stage 2
SNP ID Gene RS number NCBI
position (bp)a
Alleles
(major/minor)
MAF
Cont
(n =
SNP017 CPM rs2293637 67,551,545 C/G 0.20
SNP152 TRHDE rs7137054 71,193,410 C/G 0.44
SNP260d SYT1 rs10746105 78,213,527 C/G 0.42
SNP262d SYT1 rs10746114 78,215,902 G/A 0.42
SNP378d PPFIA2 rs11114926 80,491,943 A/T 0.29
SNP380d PPFIA2 rs1922416 80,500,960 T/A 0.29
SNP488d SOCS2 rs10777530 92,463,578 T/C 0.48
SNP489d SOCS2 rs10745657 92,475,969 A/G 0.26
SNP514 CRADD rs10859589 92,704,990 C/T 0.33
Association results of nine SNPs tested in Stage 2 are shown, along with the resul
a SNP positions were based on NCBI Build 34 human genome sequence informa
b MAF, minor allele frequencies.
c Crude odds ratio (OR) was calculated against disease-protective allele.
d There were close allelic associations between SNP260 and SNP262, SNP378 a
e NA, not assessed.of a < 0.01 (Table 1). Overall, our two-stage, step-wise
focusing design was expected to select less than one false-
positive SNP on average (since 585 SNPs were initially tested,
average numbers of false-positive markers were expected to be
59 in Stage 1 (585 SNPs at a = 0.1), 30 in Stage 1E (585 SNPs
at a = 0.05), and 0.3 in Stage 2 (30 SNPs at a = 0.01), without
taking account of allelic associations). In Stage 2, only a single
SNP, SNP488 (rs10777530), marginally reached the signifi-
cance level ( p = 0.0095, Table 1). A retrospective analysis of
the power for the significant association detected revealed that
the probabilities for detecting the differences between cases
and controls for SNP488 were 55.5% at Stage 1 (significance
level a = 0.1), 79.6% at Stage 1E (a = 0.05), and 58.2% at
Stage 2 (a = 0.01).
When all of the genotypic data were pooled (Stages 1E and 2,
a total of 781 controls and 711 T2D individuals), the crude OR
for SNP488 was 1.32 (95% CI 1.15–1.53, p = 0.00013).
Logistic regression analysis revealed that the association
between SNP488 and T2D remained statistically significant
after adjustment for age and sex (data not shown). It should be
mentioned that, when Bonferroni_s correction for multiple
analyses was applied for 585 independent tests (number of
initial SNPs), SNP488 did not reach statistical significance
(Bonferroni-corrected p = 0.076). However, because significant
LD existed in our 585 SNPs, such that they were not completely
‘‘independent,’’ Bonferroni_s correction was likely to be too
conservative. It is noteworthy that, in the pooled data set, two
other SNPs, SNP489 (rs10745657) and SNP152 (rs7137054),
were significantly associated ( p < 0.05) with T2D (SNP489, OR
1.28, 95%CI 1.10–1.50, p = 0.0019; SNP152, OR 1.20, 95%CI
1.04–1.39, p = 0.01).We could not exclude the possibility of the
associations for SNP489 and SNP152 being false positives;
however, because SNP489 was close to SNP488 and these two
SNPs were in strong LD (|DV| = 1.00), we assumed both to be
associated with the same putative susceptibility variant(s).
To determine the probability that our significant associations
were false positives, we applied the false positive report
probability (FPRP) method that was recently proposed byb p value Crude OR
(95% CI)crol
781)
Case
(n = 711)
Stage 1E Stage 2 Pooled
7 0.182 0.030 0.854 0.084 NAe
8 0.404 0.036 0.203 0.014 1.20 (1.04–1.39)
8 0.451 0.013 0.516 0.199 NAe
6 0.449 0.018 0.588 0.202 NAe
5 0.315 0.042 0.695 0.246 NAe
6 0.315 0.050 0.714 0.259 NAe
1 0.449 0.0053 0.0095 0.00013 1.32 (1.15–1.53)
7 0.319 0.025 0.036 0.0019 1.28 (1.10–1.50)
5 0.312 0.014 0.426 0.196 NAe
ts of Stage 1E and the pooled sample (781 controls and 711 cases).
tion.
nd SNP380, and SNP488 and SNP489.
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(1) the prior probability of a true association, (2) observed p
value for the association, and (3) statistical power of the study.
Since the current study was the hypothesis-driven candidate
region scan, we assigned a low to moderate prior probability
range (0.1 to 1%). To determine FPRP values, we used our
experimentally determined values of OR and the corresponding
95% CI for SNP488, SNP489, and SNP152 in the total study
group. For a prior probability of 0.1%, we obtained the FPRP
value of 0.193 for SNP488, which satisfied a stringent FPRP
value of <0.2 [27] and indicated our findings to be noteworthy
(0.701 for SNP488 and 0.938 for SNP152). For a prior
probability of 1%, the FPRP value for SNP488 was less than
5% (0.023). In addition, the FPRP value for SNP489 (0.188)
was also satisfied at a <0.2 FPRP level (the results of FPRP
analysis are summarized in Appendix C).
As a result, our association test identified two associated
SNPs, SNP488 and SNP489, as putative candidate SNPs for
Japanese T2D. The results are summarized in Table 1 and
illustrated graphically in Fig. 1.
Determination of LD block structure around SNP488–SNP489
SNP488 and SNP489 were mapped to the 5V and 3V regions of
the SOCS2 gene, respectively, with a distance of 12,391 bp.
There was strong LD between the two (|DV| = 1.00), indicatingFig. 1. Results of SNP association study on chromosome 12q. Gene-centric, evenly s
the association test. For Stages 1, 1E, and 2, 585, 37, and 9 SNPs were analyzed, r
above. Gene-centric regions (black boxes) of 128 genes are shown in the middle
distance, 12.5 kb) rather than in the intergenic regions.that both SNPs are in the same LD block. Since the length of the
LD block may have extended beyond 12 kb, and therefore might
contain a gene(s) other than SOCS2, and to investigate the LD
structure in detail and to clarify the susceptibility region, we
again searched various databases for ungenotyped SNP markers
flanking SNP488 and SNP489. We identified four new SNPs
(ZS003, SNP487, A356, and A357) in the public database and
genotyped them in all DNA panels (Stage 1E and Stage 2), along
with SNP490 used in Stage 1. LD analysis using these seven
SNPs indicated that SNP488, A356, and SNP489 belonged to
the same LD groups (|DV| > 0.99), while four other SNPs clearly
lay outside the haplotype block (ZS003–SNP487 in the
upstream region and A357–SNP490 in the downstream region;
see Appendix D).
We next conducted resequencing analysis in the ¨20-kb
interval between SNP487 and SNP490 to search for unidentified
SNPs and to determine the exact boundaries of a given haplotype
block. For this purpose, we chose genomic DNAs from 24
control individuals for direct sequencing analysis and identified
50 new polymorphic sites (49 SNPs and 1 microsatellite, data
not shown). We genotyped all DNA panels (Stage 1E and Stage
2), and the subsequent LD analysis using SNPs with MAF > 0.1
using the Haploview software [28] identified three haplotype
blocks (Fig. 2). A putative T2D susceptibility LD block as
defined by Gabriel_s rule [26] spanned a 13,584-bp genomic
region between the ZS009 and the SNP489 markers (Fig. 2,paced common SNPs on chromosome 12q15–q22 are shown with p values for
espectively. The target chromosomal region for the association study is shown
. Note that SNPs were selected mainly in gene-centric regions (average SNP
H. Kato et al. / Genomics 87 (2006) 446–458450Block 2). There were 34 polymorphic sites within Block 2 in the
Japanese population (Table 2), including one rare synonymous
coding SNP in exon 3 (ZS006; Y268Y) and two SNPs in the 5V
untranslated region of the SOCS2 gene. We also confirmed that
SOCS2 was the only gene that mapped within Block 2.
SNP haplotypes, cladistic analysis, ‘‘sliding window’’ analysis
Results of association tests for the 34 polymorphic sites in
Block 2 are shown in Table 2. We observed significant
associations with all common SNPs of MAF > 0.25 and a
microsatellite MS1, but not with rare SNPs. The most
significantly associated SNP was ZS011 (rs12425869, p =
0.000063), which was adjacent to and in complete LD (r2 = 1)
with SNP488.
To identify the putative susceptibility site(s) responsible for
the observed association in Block 2, we applied a cladistic
approach proposed by Templeton et al. [29]. This approach
allows analysis of multilocus data within a genomic segment/
gene by considering haplotypes and grouping them in nested
clades. The idea is to search for clades with an association
between haplotypes and phenotypes and to identify the
mutations defining these clades as potential candidate disease
susceptibility sites. For the analysis, we first estimated
haplotype frequencies of 22 SNPs in Block 2 that wereFig. 2. Haplotype block structure encompassing the human SOCS2 gene. Haplotype
organization of the SOCS2 gene (top). Exons are indicated by boxes (black, coding s
2) spans the region between markers of ZS009 and SNP489 encompassing the entrelatively common in terms of their frequencies (MAF > 5%)
using SNPAlyze_v.3.2.1PRO software, which is based on the
Expectation–Maximization (EM) algorithm. Five major hap-
lotypes that covered more than 97% of all haplotypes were
observed (data not shown). The SNPtagger program [30] then
revealed that these five haplotypes (Nos. 1–5) were tagged (or
identified) by four htSNPs, ZS009, ZS012, ZS004, and ZS016.
We found a significant association with T2D by the haplotype
association analysis using the four htSNPs and identified a
common disease-protective haplotype 1 (Table 3, permutation
p = 0.00051) and an at-risk haplotype 2 (permutation p =
0.00097). Finally, a cladistic-based association analysis was
performed using the Evolutionary-Based Haplotype Analysis
Package (EHAP)_v1.1 program [31]. Results showed that all
five haplotypes were connected in a cladogram according to
their evolutionary history (Table 3). In addition, the disease-
protective haplotype (1) could be discriminated from other
haplotype groups (2, 3, 4, and 5, score test p = 0.0001).
Because a single mutational step at htSNP ZS009 was
responsible for this observation, we concluded that ZS009
was most likely to be etiologically associated with the disease-
susceptibility variant.
The htSNP ZS009 represents 17 polymorphic sites within
Block 2 (Table 2). However, further application of a
conventional fine-mapping strategy appeared to be limitedblock structure following the Gabriel definition [26] is shown, along with the
equences; white, untranslated sequences). A 13,584-bp haplotype block (Block
ire SOCS2 gene.
Table 2
List of 34 DNA polymorphic sites in the SOCS2 gene (Block 2)
SNP ID RS number NCBI
position
(bp)a
Position from
SOCS2
transcription
start site
Domain Allele Genotyping
method
Frequency p value ZS009-tagged
SNPsb1 2 Control Case
Allele 1 Allele 2 Allele 1 Allele 2
ZS009 rs3869308 92,462,386 –3680 5V upstream T C TaqMan 0.476 0.524 0.542 0.458 0.00032 –
ZS010 rs10859532 92,463,385 –2681 5V upstream G C TaqMan 0.481 0.519 0.552 0.448 0.00011 #
SNP488 rs10777530 92,463,578 –2488 5V upstream C T TaqMan 0.481 0.519 0.551 0.449 0.00012 #
ZS011 rs12425869 92,463,821 –2245 5V upstream A G TaqMan 0.479 0.521 0.552 0.448 0.00006 #
ZS035 – 92,464,422 –1644 5V upstream C T Sequencing 1.000 0.000 0.995 0.005 0.33
ZS041 – 92,464,752 –1314 5V upstream [C]3 [C]2 Sequencing 0.996 0.004 0.996 0.004 0.94
ZS042 – 92,464,822 –1244 5V upstream G A Sequencing 0.998 0.002 1.000 0.000 0.33
ZS012 rs11107111 92,464,851 –1215 5V upstream T G PCR-ASP 0.723 0.277 0.669 0.331 0.00134
ZS013 rs2053196 92,465,427 –639 5V upstream T C TaqMan 0.479 0.521 0.552 0.448 0.00007 #
ZS014 rs2200160 92,466,341 +276 Exon 1 (5V-UTR) C T TaqMan 0.481 0.519 0.552 0.448 0.00010 #
ZS004 rs1498708 92,466,432 +367 Exon 1 (5V-UTR) C T TaqMan 0.833 0.167 0.832 0.168 0.93
ZS036 – 92,466,775 +710 Intron 1 T G Sequencing 0.983 0.017 0.968 0.032 0.35
ZS015 – 92,467,972 +1907 Intron 1 C A TaqMan 0.987 0.013 0.987 0.013 0.97
ZS016 – 92,468,459 +2394 Intron 1 [T]3 [T]2 TaqMan 0.855 0.145 0.860 0.140 0.66
ZS005 rs11834113 92,468,686 +2621 Intron 1 T C TaqMan 0.034 0.966 0.042 0.958 0.25
ZS017 – 92,469,295 +3230 Intron 2 G C TaqMan 0.985 0.015 0.985 0.015 0.90
A356 rs930316 92,469,503 +3438 Intron 2 A G TaqMan 0.475 0.525 0.538 0.462 0.00065 #
ZS037 rs3782415 92,470,223 +4158 Intron 2 C T TaqMan 0.526 0.474 0.461 0.539 0.00034 #
ZS018 rs768775 92,470,665 +4600 Intron 2 T C TaqMan 0.474 0.526 0.542 0.458 0.00022 #
ZS019 rs1316739 92,470,724 +4659 Intron 2 G A TaqMan 0.474 0.526 0.541 0.459 0.00029 #
ZS020 rs1316740 92,470,756 +4691 Intron 2 C A TaqMan 0.474 0.526 0.539 0.461 0.00039 #
ZS021 rs3729654 92,470,822 +4757 Intron 2 insT – TaqMan 0.528 0.472 0.462 0.538 0.00035 #
ZS038 – 92,470,858 +4793 Intron 2 [T]12 [T]11 Sequencing 0.528 0.472 0.500 0.500 0.59 #
ZS006 – 92,471,381 +5316 Exon 3 (Y268Y) A G TaqMan 0.998 0.002 1.000 0.000 0.10
ZS022 rs2072593 92,472,494 +6429 3V downstream T C TaqMan 0.474 0.526 0.539 0.461 0.00045 #
ZS023 – 92,472,932 +6867 3V downstream G A TaqMan 0.999 0.001 0.999 0.001 0.62
ZS024 rs3816997 92,473,254 +7189 3V downstream A C TaqMan 0.832 0.168 0.832 0.168 0.99
ZS039 rs10859533 92,473,784 +7719 3V downstream [C]5 [C]6 Sequencing 0.523 0.477 0.495 0.505 0.59 #
MS1c rs10594657 92,474,947 +8882 3V downstream [CA]n = 11–19 – – – – 0.00761
ZS025 – 92,475,128 +9063 3V downstream G T TaqMan 0.987 0.013 0.992 0.008 0.13
ZS026 rs11107114 92,475,395 +9330 3V downstream G A TaqMan 0.469 0.531 0.530 0.470 0.00088 #
ZS027 rs11107115 92,475,455 +9390 3V downstream A G TaqMan 0.470 0.530 0.531 0.469 0.00086 #
ZS028 – 92,475,502 +9437 3V downstream C A TaqMan 0.965 0.035 0.966 0.034 0.90
SNP489 rs10745657 92,475,969 +9904 3V downstream A G TaqMan 0.733 0.267 0.681 0.319 0.00192
a SNP positions were based on NCBI Build 34 human genome sequence information.
b Four haplotype-tagging SNPs (htSNPs) were selected with the SNPtagger program (ZS009, ZS012, ZS004, and ZS016). HtSNP ZS009 (– ) represents a total of 17 SNPs (#) including ZS009.
c MS1 was a (CA)n microsatellite (n = 11 to 19). The association test was performed using CLUMP_v.2.2 software.
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Table 3
Haplotype analysis
Solid-line circle, ‘‘disease-protective’’ haplotype; dashed-line circle; ‘‘at-risk’’ haplotype group.
a ZS009 discriminates between haplotype 1 and other haplotype groups (2, 3, 4, and 5).
b ZS016 is an insertion/deletion polymorphism (TTT and TT, a deletion type, are the major and minor allele types, respectively).
c Each haplotype frequency is estimated in 781 controls and 711 cases.
d Empirical p values are derived by permutation using 100,000 replicates.
e Haplotype cladogram and its segregation according to the disease status. Observed haplotypes are depicted as filled circles whose sizes reflect haplotype
frequency.
H. Kato et al. / Genomics 87 (2006) 446–458452because these 17 SNPs were highly correlated with one
another (r2 > 0.8, data not shown) and showed similar results
in single-locus association tests at their loci (Table 2). To
obtain the best partition of haplotypes associated with T2D,
we employed a sliding window analysis using the HTR
program [32], which compares, in cases and controls, the
frequencies of haplotypes generated with a specified number
(window size) of contiguous markers. We assumed that the
sliding window approach might better localize the region
encompassing disease-susceptibility variants since it would
give a quantitative idea of the signal observed in the
‘‘background.’’ As shown in Fig. 3, results with window
sizes of 2 (two-locus) and 3 (three-locus) clearly indicated
SNPs in the 5V region of the SOCS2 gene to be associated
with an increased risk for T2D with high statistical
significance. The strongest association was observed with a
pair of SNPs, ZS011–ZS013 ( p = 0.000035, two-locus) and
a trio of SNPs ZS011–ZS013–ZS014 ( p = 0.000019, three-
locus). We tested with window sizes up to 6 and the results
were essentially the same (data not shown). SNPs ZS011,
ZS013, and ZS014, together with two additional SNPs
(ZS010 and SNP488), were in perfect LD with each other
(r2 = 1), locating within a 2955-bp genomic segment that
included noncoding exon 1 and the 5V flanking region of the
SOCS2 gene. The locations of the SNPs relative to the
putative SOCS2 transcription start site were as follows: S010,
2681 bp; SNP488, 2488 bp; ZS011, 2245 bp; ZS013,
639 bp; ZS014, +274 bp. Frequencies of the at-risk haplotype
(ZS010–SNP488–ZS011–ZS013–ZS014, G-C-A-T-C) and
protective haplotype (C-T-G-C-T) were 0.481 and 0.519 in
controls and 0.552 and 0.448 in T2D, respectively. The at-risk
haplotype was associated with T2D and the association was
statistically significant even after adjusting the regression for
age and gender (crude OR 1.33, 95% CI 1.08–1.63, p = 8.8 
105, adjusted OR 1.37, 95% CI 1.14–1.66, p = 0.00098).Based on our observations, we concluded that these five
SNPs in the regulatory region of the SOCS2 gene are
promising candidates for T2D susceptibility markers in the
Japanese population.
Association study of SOCS1 and SOCS3 genes
SOCS2 belongs to the SOCS gene family, which has at least
eight members (SOCS1 –7 and CIS) [33]. Among SOCS
proteins, SOCS1 and SOCS3 are known to be natural inhibitors
of cytokine signaling and also to influence insulin signaling (for
a review, see [34]). Therefore, in addition to the SOCS2 gene,
we speculated that SOCS1 and SOCS3 genes might also be
good candidates for involvement in the development of both
T1D and T2D. In fact, Gylvin et al. [35] previously searched for
SOCS3 mutations in Danish subjects and reported an associa-
tion between homozygosity for a 920 C-A promoter
polymorphism and increased whole-body insulin sensitivity in
young healthy unrelated individuals. To test this hypothesis in
Japanese subjects, we selected SNPs in the SOCS1 (SNP
SC003, 004, 005, and 006) and SOCS3 (SNP S3C01, 11, 08, 02,
13, 09, 10, 12, 04) genes, based on our Gene-Centric, Evenly
Spaced Common SNPs criteria (see Selection of SNPs) and
tested for association in our population (information on SNPs
and results of the association study are provided in Appendix
E). No significant differences in allelic frequencies of the SNPs
between cases and controls were detected, suggesting that
neither the SOCS1 nor the SOCS3 gene plays a major role in
conferring increased susceptibility to T2D in our population.
Expression and functional testing of the SOCS2 gene product
We analyzed the levels of SOCS2 mRNA expression in
different human and mouse tissues and cell lines (Fig. 4). In
adult human tissues, a clear differential expression of SOCS1 –
Fig. 3. Results of sliding window analysis in Block 2. Association results for single (top) and sliding windows of two or three SNP haplotypes (bottom) are shown.
Each SNP marker is plotted by relative position from the transcription start site of the SOCS2 gene (shown below). The p values for association are plotted on the
ordinate by log scale. Note that association results with window sizes of 2 (two-locus) and 3 (three-locus) clearly indicate that SNPs in the 5V region of the SOCS2
gene are associated with T2D with high statistical significance.
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the prostate and uterus and relatively low in insulin target
tissues such as the liver, skeletal muscle, and adipose. SOCS1
was more abundantly expressed, with relatively high levels in
many other tissues, such as the lung, prostate, uterus, and
placenta. SOCS3 expression was high in adipose, lung, and
aortic tissues. In mice, Socs2 expression was again relatively
low in peripheral tissues such as fat, compared to the brain
(Fig. 4B). Although we tested only a limited number of cell
lines, pancreatic h-cell lines (MIN6, NIT1) apparently
expressed relatively high levels of Socs2 (Fig. 4C).
Because expression data suggest no immediate functional
relevance of the SOCS2 gene in diabetes pathophysiology, we
conducted functional screens using an adenovirus-mediated
SOCS2 overexpression system. First, glucose-induced insulin
secretion was evaluated by overexpressing SOCS2 in MIN6 or
isolated rat islets (Figs. 5A and 5B). Interestingly, SOCS2
overexpression resulted in significantly decreased glucose-
stimulated insulin secretion in both MIN6 (Fig. 5B, Ad-SOCS2
vs control, 72.9 T 2.7 vs 94.7 T 4.0 ng ml1, n = 3, p < 0.001)
and islets (20.5 T 2.1 vs 25.9 T 1.9 ng ml1, n = 5, p = 0.003).
It is noteworthy that, even in untreated MIN6 cell extracts,
endogenous SOCS2 protein was detectable using standard
Western blot techniques (Fig. 5A, lane.1), confirming ourSOCS2 expression results. We also tested whether overexpres-
sing SOCS2 in 3T3-L1 adipocytes affects glucose uptake in
response to insulin stimulation; however, no significant
difference was observed (data not shown).
Discussion
The current study was designed to determine whether the
gene(s) located on chromosome 12q is associated with sus-
ceptibility to T2D in the Japanese population. It should be
mentioned that, in the Japanese, no linkage study has identified
chromosome 12q as a definitive region conferring susceptibil-
ity to T2D. However, we hypothesized that the T2D
susceptibility gene is likely to be shared among different racial
groups, as seen with the PPARG and KCNJ11 genes. When the
study was initiated in 2001, there were several uncertainties
regarding the accuracy and influencing factors for haplotype
inference in random population samples using the EM
algorithm, which were later extensively investigated in
simulation models and with actual haplotype data [36–38].
Therefore, in this study, we focused on the gene-coding regions
on 12q15–q22 and chose SNPs yielding priorities in their
locations and allele frequencies, rather than relying on LD
information. Recently, Phase I and II results of the International
Fig. 4. SOCS2 gene expression analysis. (A) Quantitative expression analyses of human SOCS1(hSOCS1), 2 (hSOCS2), and 3 (hSOCS3) genes in various normal
human tissues. Data are presented as the average expression levels after normalization to expression of the human G3PDH gene. Expression level of each gene in the
brain is set arbitrarily as 1.00. (B) Mouse Socs2 (mSOCS2) expression in adult mouse tissues. Data are presented as the average expression levels after normalization
to expression of the mouse h-actin gene. Relative expression levels are shown with the Socs2 expression level in the brain set arbitrarily as 1.00. (C) Expression of
mouse Socs1 (mSOCS1), 2 (mSOCS2), and 3 (mSOCS3) in cultured cell lines is shown. L1, 3T3-L1 preadipocytes; NIT1, a pancreatic h-cell line established from a
transgenic NOD/Lt mouse; MIN6B, mouse insulinoma-derived cell line; C57BL, C57BL/6 mouse pancreas. The expression levels of mouse Socs1, 2, and 3 were
standardized for h-actin. Expression level of each gene in the L1 cells is set arbitrarily as 1.00.
H. Kato et al. / Genomics 87 (2006) 446–458454HapMap Project, with the increased density of the map to one
SNP every kilobase, became available [39,40]. It is now hoped
that these results will facilitate the identification of the
haplotype blocks and the common haplotypes in the human
genome and the definition of an optimum set of tag SNPs for
more cost-effective large-scale genetic association studies.
Our results indicate, for the first time, that the SOCS2 gene is a
potential candidate gene for T2D. SNPs significantly associated
with Japanese T2D (best SNP: ZS011 (rs12425869), p = 6.3 
105) were located within a 13,584-bp block of LD (Block 2)
that contained the entire SOCS2 gene region. We identified 34
polymorphic sites within Block 2; however, none of these SNPs
were predicted to effect amino acid change. Interestingly, a
sliding window method of haplotype analysis indicated SNPs
mapped to the 5V region of the SOCS2 gene to be associated with
T2D with a high statistical significance. These findings
prompted us to speculate that nucleotide changes in the
regulatory region of the SOCS2 gene might lead to functional
consequences in terms of SOCS2 gene expression and alter
susceptibility to T2D. However, a search for potential transcrip-
tion factor bindingmotifs in the SNP sites revealed no suchmotif
(TRANSFAC database [41], data not shown). Promoter reporter
gene assays using luciferase reporter gene constructs containing
the at-risk haplotype (ZS010–SNP488–ZS011–ZS013–ZS014, G-C-A-T-C) are under way in our laboratory, but we
have not yet observed any obvious changes in HEK293 or HeLa
cells (data not shown). Since an effect on gene function is likely
to be small in common disorders like T2D, it is possible that our
artificial assay system may not be sensitive enough to detect and
assess such subtle effects of SNPs.
The SOCS2 gene product is a member of the SOCS family,
which has at least eight members (SOCS1 –7 and CIS, the
cytokine-inducible SH2 domain-containing protein). It has
been suggested that SOCS family proteins participate in
negative feedback loops in cytokine and growth factor
signaling via multiple distinct mechanisms [42,43]. Among
the SOCS proteins, SOCS1 and SOCS3 in insulin-sensitive
tissues have been shown to increase in insulin-resistant states,
such as obesity and endotoxemia. They were also shown to
attenuate insulin signaling by binding to the insulin receptor
(IR) and inhibiting phosphorylation of insulin receptor
substrates 1 and 2 (IRS-1 and IRS-2) [44]. To date, no in vitro
experimental data indicating an association between SOCS2
protein and IR signaling have been obtained. SOCS2 protein
instead acts as a negative regulator of the growth hormone
(GH) and insulin-like growth factor-1 (IGF-1) signaling path-
ways [45,46]. SOCS2 has been shown to bind to the GH
receptor and inhibit GH signaling by multiple mechanisms, for
Fig. 5. Functional screen of SOCS2 protein. (A) Construction of the SOCS2 adenovirus vector (Ad-SOCS2) and endogenously expressed SOCS2 protein in MIN6
cells. Relative levels of SOCS2 protein in MIN6 cells were determined after infecting cells with different amounts of the Ad-SOCS2 adenovirus. Ad-GFP is a control
GFP adenovirus. Numbers in parentheses indicate viral titers used for each infection. Whole-cell lysates were prepared at day 3 after infection and were analyzed by
immunoblotting using anti-SOCS2 antibody. (B) Effects of SOCS2 overexpression in MIN6 cells and isolated pancreatic islets on glucose-induced insulin secretion.
Insulin release, stimulated with 16.8 mM glucose in MIN6 cells (right) and islets (left) under static incubation conditions, was inhibited by overexpression of SOCS2
(Ad-SOCS2). Results are expressed as the means T SE (n = 3–5). *p < 0.05, **p < 0.01.
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mice exhibit gigantism characterized by increased body weight
and length [47], though neither T2D nor diabetes-related
phenotypes were reported in these mice. Importantly, the GH/
IGF-1 axes are known to be important mitogenic signal
transduction pathways in h cells [48]. Pancreatic h cells
express both GH and IGF-1 receptors [49]. GH has been shown
to stimulate insulin gene transcription, biosynthesis, and
secretion and to increase h-cell proliferation. In mice, GH
receptor gene deficiency (GHR/) resulted in elevated insulin
sensitivity and diminished pancreatic islet cell mass and serum
insulin levels [50]. Mice lacking both IGF-I receptors and IRS-
2 show a marked reduction of h-cell mass and die from
diabetes due to h-cell insufficiency [51], indicating that IGF-1
receptors couple to IRS-2 in pancreatic islets to mediate h-cell
development, proliferation, and survival. From these observa-
tions, the dysregulation of SOCS2 might potentially attenuate
GH and/or IGF-1 signaling in h cells and thereby lead to loss
of h-cell mass and diabetes. Of note, our preliminary
experiments with adenoviral-mediated overexpression ofSOCS2 in MIN6 cells or isolated rat islets showed a 25%
suppression of glucose-stimulated insulin secretion. This
suggests that increased SOCS2 protein in h cells impairs
insulin biosynthesis/storage or glucose sensing, although the
exact cellular mechanism is not known at present.
In summary, in the current study, we identified SOCS2 as a
new candidate gene for T2D in the Japanese population. We
also obtained detailed information about polymorphic DNA
sites and haplotype divergence in the SOCS2 gene region.
Although we carefully designed the study protocol to minimize
both false positive and false negative association results, this
study was no more than a single population-based case–control
study. Therefore, replication studies in other independent
populations, especially in those in which linkage has been
reported, or family-based tests of association are priorities for
determining the consistency of our observations. Obviously,
future assessment of a quantitative effect of the associated
haplotypes on phenotypes will greatly facilitate understanding
the physiology. The function and mechanism of SOCS2 action
in pancreatic h cells also need to be elucidated.
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Subjects
The study was conducted in accordance with the tenets of the Declaration of
Helsinki. All subjects consented to participate in this study in accordance with
the process approved by the Ethical Committee for Human Genome and Gene
Research at the University of Tokushima. A total of 711 Japanese individuals
with T2D (47.3% women; mean age 62.6 T 11.4 (SD) years; mean BMI 23.7 T
3.40 (SD)) and 781 control individuals (54.9% women; mean age 40.6 T 16.3
(SD) years; mean BMI 22.0 T 3.05 (SD)) were recruited mainly from the Eye
Clinic at Tokushima University Hospital and Kyoto Prefectural University
Hospital and its affiliates. The diagnosis of T2D was made either by the 1985
WHO criteria [52] or by being treated with medications for diabetes. Genomic
DNA samples were extracted from peripheral blood leukocytes or EB virus-
immortalized B lymphoblasts according to a standard method. Some genomic
DNA samples were amplified prior to genotyping using the GenomiPhi DNA
Amplification Kit (Amersham Biosciences, Uppsala, Sweden).
SNP genotyping
Most SNPs were genotyped by TaqMan assays [25] according to the
manufacturer_s protocol with modifications, using commercially available
reagents (TaqMan Universal PCR Mastermix, No UNG, TaqMan SNP
Genotyping Assays, Custom TaqMan SNP Genotyping Assays; Applied
Biosystems, Foster City, CA, USA). Our success rate for allele-calling in the
Stage 1 study was 99.86% (=177,595/177,840 genotypes, 585 SNPs  304
subjects). Genotyping accuracy was assessed as follows: 30 SNPs were
randomly chosen and genotypes of 32 subjects were determined by direct
sequencing analysis and compared with the results of TaqMan assays.
Genotype concordance between the two genotyping methods was 100%
(959/959 genotypes, a single assay resulted in an ‘‘undetermined’’ genotype and
was excluded from the calculation).
In the case of SNPs being problematic in designing TaqMan probes or
optimizing assays, PCR allele-specific primer (PCR-ASP) assays [53] or direct
sequencing assays were used for genotyping. In PCR-ASP assays, the amount
of PCR product amplified with allele-specific primers was monitored using the
ABI Prism 7900HT sequence detection system (Applied Biosystems) with
fluorescent double-strand DNA binding dye (SYBR Green PCR Master Mix;
Applied Biosystems). Genotypes were identified by comparing the amount of
each allele-specific amplicon. For the PCR direct sequencing analysis, PCR
amplicons (averaging 500–600 bases in length) were sequenced directly from
both sense and antisense ends with an ABI Prism BigDye Terminator Cycle
Sequencing-Ready Reaction Kit (version 1.1 or 3.1; Applied Biosystems) using
automated sequencers (ABI Prism 3100 genetic analyzer and Applied
Biosystems 3730xl DNA analyzer; Applied Biosystems). One microsatellite
(MS1) was genotyped by electrophoresing the fluorescence-labeled PCR
amplicons with an automated sequencer (Applied Biosystems 3730xl DNA
analyzer; Applied Biosystems) followed by analysis using GeneMapper_v3.0
(Applied Biosystems).
Genetic computer software
Computer software programs used in this study were as follows:
(1) CLUMP_v.2.2 (http://www.mds.qmw.ac.uk/statgen/dcurtis/software.
html): we used this software to test for association with a microsatellite
marker, MS1. The CLUMP program is based on the Monte Carlo
method of assessing the significance of association with each allele of a
microsatellite [54].
(2) Haploview_v.3.0 (http://www.broad.mit.edu/mpg/haploview/
index.php): we used this free software to analyze and visualize the
LD and haplotypic patterns [28].
(3) SNPAlyze_v.3.2.1PRO (http://www.dynacom.co.jp/products/package/
snpalyze/): we purchased this software from Dynacom Co., Ltd.
(Yokohama, Japan). The SNPAlyze program estimates haplotype
frequencies by employing the EM algorithm and compares haplotypefrequencies in cases and controls using a likelihood ratio test [55]. In the
present study, we calculated empirical p values by using permutation
tests for 1,000,000 replicates.
(4) HTR (http://statgen.ncsu.edu/zaykin/htr.html): the HTR program esti-
mates haplotype frequencies using the EM algorithm and then relates the
inferred haplotype frequencies to the observed phenotype using a
regression model [32]. In the present study, we calculated empirical p
values by using permutation tests for 1,000,000 replicates. The HTR also
provides a sliding windowmode of haplotype association analysis, which
compares, in cases and controls, the frequencies of haplotypes generated
with a specified number (window size) of contiguous markers.
(5) Haplo.stats_v.1.1.1 (http://www.mayo.edu/hsr/people/schaid.html): this
free software requires the open source statistical programming package
R (available at http://cran.r-project.org/) to run. The Haplo.stats
programs assigns a probability for each haplotype pair in each
individual and then models an individual_s phenotype directly as a
function of each inferred haplotype pair to account for haplotype
ambiguity [56,57]. With this program, analysis with adjustment for
covariates and computation of simulation p values for each haplotype
can be performed. In the present study, we controlled for age and sex as
covariates and compared unadjusted and adjusted results.
(6) EHAP_v.1.1 (http://wpicr.wpic.pitt.edu/WPICCompGen/): we used this
program for the cladistic-based association analysis, pioneered by
Templeton et al. [29]. The EHAP utilizes information contained in the
evolutionary relationships among haplotypes and in the sample using
generalized linear models. A sequential test series is performed first
considering haplotypes that fall into the external nodes of the cladogram
(zero-step clades) and then considering one-step clades (produced by
moving backward one mutational step from the zero-step clades toward
internal nodes), two-step clades, and so forth. From an ancestral
haplotype, polymorphisms lead to the observed diversity of haplotypes,
which is summarized in a cladogram. By assessing the distribution of
phenotypes within a cladogram, it is possible to search for the putative
causal polymorphism (mutation) with an increased statistical power.
(7) SNPtagger (http://www.well.ox.ac.uk/¨xiayi/haplotype/index.html): we
used this World Wide Web-based program to search for minimal htSNPs
from inferred haplotypes.
(8) FPRP calculation sheet (http://jncicancerspectrum.oxfordjournals.org/
cgi/content/full/jnci;96/6/434/DC1): Wacholder et al. recently proposed
a measure called false positive report probability to assess the likelihood
that a molecular epidemiological finding is a false positive [27]. The
FPRP requires prior estimation of the probability that a gene is
associated with the phenotype and is compatible with the Bayesian view
that the prior credibility of the hypothesis should influence evaluation of
association studies. To obtain FPRP values, the estimated prior
probability range, the statistical power to detect an OR of 1.5, and
observed ORs and 95% confident intervals were entered into the
calculation sheet provided by Wacholder et al. [27].
Expression analyses
Quantitative RT-PCR analyses to estimate the expression of human and
mouse SOCS1 –3 were performed using an ABI Prism 7900 sequence detection
system (Applied Biosystems) with SYBR Green PCR Master Mix (Applied
Biosystems), following the manufacturer_s instructions. The primers for
detecting mRNA of human SOCS1 –3 were SOCS1 (NCBI Reference Sequence
NM_003745), hSOCS1F, 5V-TAGCACACAACCAGGTGGCA-3V, and
hSOCS1R, 5V-GCTCTGCTGCTGTGGAGACTG-3V; SOCS2 (NM_003877),
hSOCS2F, 5V-CCTTTATCTGACCAAACCGCTCTA-3V, and hSOCS2R, 5V-
TGTTAATGGTGAGCCTACAGAGATG-3V; SOCS3 (NM_003955),
hSOCS3F, 5V-TCTCTGTCGGAAGACCGTCAA-3V, and hSOCS3R, 5V-
CGGCAGCTGGGTGACTTT-3V. The primers for detecting mouse Socs1 –3
mRNAs were Socs1 (NM_009896), mSOCS1F, 5V-GGCACCTTC-
TTGGTGCGC-3V, and mSOCS1R, 5V-AAGCCATCTTCACGCTGAGC-3V;
Socs2 (NM_007706), mSOCS2F, 5V-ATATCCGTTAAGACGTCAGCTGG-3V,
and mSOCS2R, 5V-TATGATAGAATCCAATCTGAATTTCCC-3V; Socs3
(NM_007707), mSOCS3F, 5V-CAAGACCTTCAGCTCCAAAAGC-3V, and
mSOCS3R, 5V-CTCCAGTAGAATCCGCTCTCCT-3V. SOCS1 –3 gene expres-
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mouse mRNA. The primer pairs used for human G3PDH and mouse h-actin
were hG3PDH-F, 5V-GGGAAGGTGAAGGTCGGA-3V, and hG3PDH-R, 5V-
GCAGCCCTGGTGACCAG-3V; mh-actinF, 5V-TCTGTGTGGATCGGTGGC-
3V, and mh-actinR, 5V-GCTGATCCACATCTGCTGGA-3V. All oligonucleotides
were purchased from ProOligo (Lismore, NSW, Australia).
Total RNA was extracted from the pancreas of C57BL/6 mice and various
cell lines (L1, NIT1, and MIN6), using the RNeasy kit (Qiagen N.V., Venlo,
The Netherlands) or Isogen reagents (Nippongene, Toyama, Japan). Total RNA
was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen,
Carlsbad, CA, USA) and random hexamer primers to generate first-strand
cDNA. Human cDNA was purchased from BD Biosciences Clontech (Palo
Alto, CA, USA) or the Biochain Institute (Hayward, CA, USA).
Adenovirus construction
Adenoviruses containing mouse Socs2 were constructed as previously
described [58]. Full-length mouse Socs2 cDNAs were generated by RT-PCR
with forward primer 5V-CGGGGTACCGCCATGACCCTGCGGTGCCTG-
GAGCCCTCC-3V and reverse primer 5V-CCGCTCGAGTTATACCTGGAATT-
TATATTCTTCCAA-3V; the KpnI and XhoI sites included in these primers are
underlined. The cDNA fragment was then inserted into the KpnI –XhoI site of
the pAdTrack-CMV vector [58], and the adenoviruses were replicated and
amplified in HEK293 cells.
Adenovirus-mediated overexpression of SOCS2in MIN6 cells or rat islets
was achieved as previously described [59], with concentrations of 108 pfu/ml
for MIN6 cells and 106 pfu/ml for islets. For Western blotting, the MIN6 cell
lysate was boiled in the SDS sample buffer with 10 mM dithiothreitol and then
applied to SDS–PAGE and transferred onto to a polyvinylidene difluoride
membrane (Immun-Blot PVDF Membrane; Bio-Rad Laboratories, Hercules,
CA, USA). The membrane was incubated with primary anti-SOCS2 antibody
(AnaSpec, Inc., San Jose, CA, USA) and thereafter with horseradish
peroxidase-conjugated secondary antibody.
Glucose-induced insulin secretion test in MIN6 and isolated rat islets
The mouse insulinoma cell line MIN6 [60] was grown in DMEM
containing 15% (v/v) heat-inactivated fetal calf serum (Invitrogen), 100 IU
ml1 penicillin, and 100 mg ml1 streptomycin. Cells were cultured in a
humidified atmosphere with 5% CO2 at 37-C. Pancreatic islets were isolated
from 6- to 8-week-old fed Wistar rats (CLEA Japan, Inc., Tokyo, Japan) by
collagenase digestion in conjunction with Ficoll gradient separation. Islets were
hand-picked under the microscope and cultured overnight in RPMI 1640
medium containing 10% (v/v) heat-inactivated fetal calf serum (Invitrogen).
For glucose-induced insulin secretion testing, MIN6 cells or isolated rat
islets were washed in Krebs–Ringer bicarbonate (KRB) buffer supplemented
with 2.8 mM glucose, 0.1% BSA, and 10 mM Hepes (pH 7.4) in 24-well
dishes. Cells and islets were then preincubated at 37-C for 1 h and further
incubated for 20 min (MIN6) or 1.5 h (islets) in the KRB buffer containing 2.8
or 16.8 mM glucose. Insulin concentrations in the medium were determined
with an insulin radioimmunoassay kit (Amersham Biosciences, Buckingham-
shire, England) using rat insulin as a standard. All data are presented as means T
SE. Student_s t test was used to determine the significance of differences
between groups.
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